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Key Clinical Message
Acute life-threatening intoxications with insecticides are rare. We report a case
of accidental near-fatal thiacloprid intoxication with mass spectrometry-based
analytical confirmation. The initial clinical presentation resembled imminent
brain death and/or severe postanoxic encephalopathy. Prolonged supportive
treatment resulted in full recovery underlining intoxication as an important dif-
ferential diagnosis in unclear coma.
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Introduction
Neonicotinoids are widely used insecticides with several
compounds being commercially available (imidacloprid,
thiacloprid, acetamiprid) [1–3]. Neonicotinoids act as
agonists on nicotinic acetylcholine receptors (nAChRs)
inducing the disruption of neural transmission in the cen-
tral nervous system via mimicking of neurotransmitter
action and/or continuous nerve stimulation or blocking
[1, 4–6]. Tissue penetration and translocation characteris-
tics account for a relevant toxicity in insects resulting in
paralysis, cellular exhaustion, and death [7]. Importantly,
differences in nAChR subtypes/specificity of binding sites,
reduced nAChR expression, and poor mammalian blood–
brain barrier penetration account for an assumed low
toxicity in vertebrates [4, 7–12]. Classification of thiaclo-
prid toxicity is largely based on animal data with poten-
tial differences between specific products [12, 13].
Reports on acute life-threatening intoxications with
neonicotinoids in humans are rarely observed on inten-
sive care units and are mostly limited to acetamiprid and
imidacloprid [14]. Few previous reports exist on fatalities
following acute thiacloprid intoxication [15]. Here, we
present a case of a near-fatal acute accidental thiacloprid
intoxication. Subsequent complete recovery was observed
after a prolonged course of extensive supportive intensive
care treatment.
Case History
A 72 year-old previously healthy Caucasian male prepared
coffee in a hunting cabin in the woods. From a nearby win-
dowsill a “milk” bottle was grabbed and a substantial
amount (around 100–200 mL) added to a “Cafe au Lait.”
Although the patient noticed the last “milk” drops got
fluffy, he finished his “Cafe au Lait” in one go. About
15 min later, severe nausea and repeated vomiting was
noted and emergency teams were called for by his fellow
hunters. When paramedics arrived at the scene, an uncon-
scious patient with lateralized convulsions was noted, and
benzodiazepines administered. After cessation of convul-
sions, the patient was transported to a rural emergency
ª 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
1
department with coma of unknown origin. Persisting coma
subsequently required mechanical ventilation. Predomi-
nantly facial and thoracal myoclonia developed shortly
thereafter, and hypothermia (core body temperature
31.8°C), progressive metabolic acidosis (pH 7.09, HCO3

14 mmol/L) with increased serum lactate (6 mmol/L),
hypokalemia (2.6 mmol/L), and hypocalcaemia
(1.91 mmol/L) was noted. Repeated testing of serum glu-
cose levels returned normal. Despite adequate fluid resusci-
tation, volume-refractory hemodynamic shock with need
for high-dose noradrenaline was noted (0.7 mcg/kg/min).
A cerebral contrast-enhanced CT scan returned normal.
Treatment at Tertiary Care Unit
The differential diagnosis of unclear persisting coma with
acute-onset typically embraces cerebral vascular disorders/
stroke, seizures, advanced cerebral or systemic infections,
(traumatic) brain injury, hypo- (or hyper) glycemia,
postanoxic/postcardiac arrest, organ failure-related (incl.
endocrine disease), metabolic/electrolyte-induced, and
importantly, intoxications (e.g., alcohols). After retrieval
of the presumed “milk bottle” (thiacloprid concentration:
480 g/L), severe accidental acute thiacloprid intoxication
appeared obvious and transfer to our tertiary care aca-
demic center was performed. At ICU admission, an intu-
bated comatose patient with progressive metabolic
acidosis (pH 6.9) and hyperdynamic volume-refractory
vasoplegic shock was noted. As metabolic acidosis was
unresponsive to sodium bicarbonate infusions, emergency
hemodialysis was performed (Fig. 1A, blood flow
250 mL/min., dialysate flow 600 mL/min., bicarbonate
dialysate, urea reduction rate approx. 44%, kt/V 0.91).
The diagnosis was confirmed analytically with levels of
thiacloprid and metabolites being followed up by mass
spectrometry (Fig. 1). Supportive care was continued, and
metabolic acidosis and hemodynamic shock gradually
improved over the subsequent 12–24 h.
Figure 1. Evolution of thiacloprid and metabolite levels in plasma and urine. Course of plasma (A) and urinary (B–D) levels of thiacloprid or
metabolites (LC-MS). (1A): Time of hemodialysis is given (a, b); dotted line: linear regression line day 1–3. (B) Course of relative intensity of the
main compound in urine (%), (C) relative urinary concentrations of key metabolites, and (D) absolute urinary metabolite intensities are given.
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Repeat neurological examination off sedatives revealed
a comatose patient (GCS 3) with maximal dilated and
fixed pupils, absent corneal and vestibulo-ocular reflexes
without reaction to painful stimuli. Intermittent irregular
multifocal facial and (mostly upper) extremity myoclonus
with “hemiballistic-type” movements most likely due to
disrupted neurotransmission and/or altered nerve conduc-
tion velocity were noted (Video S1). Electroencephalogra-
phy showed alpha-theta waves without status epilepticus
and only minimal variability and responsiveness to stim-
uli. Cerebral MRI demonstrated minor cortical diffusion
restriction in the postcentral gyrus.
Outcome and Follow Up
On day 2 (serum levels <30 mg/L, Fig. 1A), neurologic
improvement was noted with reversal of coma, sponta-
neous eye opening, obeying of simple commands, but
persistence of extensive myoclonus. Over the ensuing
days, steady neurological improvement was observed, and
extubation was performed on day 4. On day 8, the patient
had fully recovered and was discharged home.
Discussion
Human data on severe acute intoxications with thiaclo-
prid are sparse [15]. Here, repeat analysis of the patient’s
plasma and urine levels for the main thiacloprid com-
pound as well as key metabolites was performed using
liquid chromatography mass spectrometry (LC-MS)
(Fig. 1A–D). Serial assessment of toxin levels by LC-MS
in plasma and urine revealed progressive and near-com-
plete decrease in thiacloprid levels (blood: 76.05–
0.011 mg/L) until ICU discharge at day 4 (Fig. 1A–D).
A decline in thiacloprid plasma concentrations was
observed until day 3 (Fig. 1A, dotted line: linear regres-
sion day 1 to day 3). Unfortunately, neither blood sam-
ples drawn exactly before and after hemodialysis, nor
dialysate samples were available for technical reasons and
we can thus only speculate on whether toxin removal can
be achieved by hemodialysis. However, in goats, hens,
and rats, thiacloprid elimination was described to mainly
occur via the renal route, with hydroxylation and glu-
curonidation being key initial metabolic steps (http://disse
mination.echa.europa.eu/Biocides/ActiveSubstances/0053-08/
Data_002.pdf. assessed 11 December 2016). Interestingly,
a rather constant decline of thiacloprid blood levels was
observed over the whole concentration range during the
days following the dialysis procedure (Fig. 1A) which
might theoretically hint to a zero order kinetic by an
active saturable transport rather than “simple” free
glomerular filtration. Extracorporeal elimination using
hemodialysis might therefore be of benefit to overcome
the limited renal elimination capacity especially during
the initial phase with very high thiacloprid blood concen-
trations. To the best of our knowledge, however, a formal
volume of distribution and plasma protein binding char-
acteristics in humans are unknown and it should be kept
in mind that plasma thiacloprid concentrations may not
adequately reflect the degree of clinical severity [14]. Nev-
ertheless, rescue hemodialysis might be considered in
severely intoxicated patients for reasons beyond control of
severe metabolic acidosis.
Conclusion
In conclusion, acute life-threatening thiacloprid intoxica-
tion is rarely observed in humans. The clinical presenta-
tion may masquerade as coma with clinical signs of
imminent brain death and/or severe myoclonic status due
to postanoxic encephalopathy. Despite an initial at a first
glance futile clinical presentation, rare cases of severe
intoxications must be considered when treating patients
with persisting and unexplained coma. In cases with thia-
cloprid intoxications, prolonged supportive intensive care
treatment seems indicated.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Video S1. Clinical presentation of intoxicated patient.
Neurological presentation of the patient 24 h following
ICU admission.
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